Dividend bonanza alert! This Pharma stock shares jump 11% after Rs 165 per share payout — biggest in 5 years

In a development that has got Dalal Street abuzz, Pfizer India shares rose 11 per cent on Tuesday, May 20, after the company declared a staggering dividend of Rs 165 per share, its biggest dividend in five years. The dividend announcement was made alongside the company’s March quarter performance when both profitability and margins significantly improved.

Dividend Announcemnet

• Rs 35 per share as ordinary dividend
• Rs 100 per share as a special dividend in celebration of Pfizer’s 75 years in India
• Rs 30 per share as an extra special dividend in consequence of a one-time gain on the transfer of leasehold land and building
• The aggregate payout comes to Rs 165 per share. The record date for the dividend has been declared on July 9, 2025.

Quarter 4 Performance

Pfizer announced an 8 per cent increase in revenue in the March 2025 quarter against the corresponding quarter last year. EBITDA jumped 20 per cent year-on-year and a huge 56 per cent sequentially from the December quarter.

One of the key highlights was the EBITDA margin expansion, which surged by 11 percentage points to 38.4 per cent, from 27.1 per cent in the same quarter last year — reflecting strong operational efficiency and cost control.

Stock Movement

After the bumper dividend and strong finances, shares of Pfizer soared 11 per cent to Rs 4,961.5 on the NSE, ranking among the day’s top gainers. The company has given an enormous 18 per cent return in a single month, surpassing even the broader pharma index as well as the Nifty 50.

Last mega dividend was in 2020

This Rs 165 payment is the largest dividend declared by Pfizer after May 2020, when it had given a special dividend of Rs 320 per share. With this, Pfizer solidifies its image as a steady generator of wealth for long-term shareholders.

Why investors are positive about Pfizer India

• Completion of 75 years in India reflects market confidence over the long term
• Regular dividend payments enhance shareholder value
• Margin expansion indicates robust cost management and pricing authority
• A return of more than 18 per cent within 30 days makes the stock a defensive bet
   

Major triggers ahead

Pfizer’s show in the vaccine and speciality drug businesses will continue to be important. Analysts are looking for sustained margin robustness and healthy dividend payouts to drive valuations in the medium term.

With its Rs 165 per share dividend, strong books, and increasing stock price,  Pfizer India has come into focus as a high-dividend pharma play to watch out for in 2025. Retail and institutional investors are now looking for the July 9 record date — and maybe more gains to come.